Published in:
Open Access
01-12-2016 | Letter to the Editor
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
Authors:
Giovanni Caocci, Marianna Greco, Giuseppe Delogu, Christian Secchi, Bruno Martino, Claudia Labate, Elisabetta Abruzzese, Malgorzata Monika Trawinska, Sara Galimberti, Federica Orru, Claudio Fozza, Carlo Gambacorti Passerini, Francesco Galimi, Giorgio La Nasa
Published in:
Journal of Hematology & Oncology
|
Issue 1/2016
Login to get access
Abstract
We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR as the telomere to single copy gene (36B4) ratio normalized to a reference sample (K-562 DNA). Age-corrected RTL (acRTL) was also obtained. The 36-month probability of treatment-free remission (TFR) was 59.4 %. TFR patients showed shorter acRTL compared to relapsed (mean ± SD = 0.01 ± 0.14 vs 0.20 ± 0.21; p = 0.01). TFR was significantly higher in CML patients with acRTL ≤0.09 (78.9 vs 30.8 %, p = 0.002). CML stem cells harboring longer telomeres possibly maintain a proliferative potential after treatment discontinuation.